The highlight has shone on Bionano Genomics (BNGO) in 2021. The everyday living sciences organization is getting a whole lot of attention because of to Saphyr, its genome imaging system, and the purpose it can play in reworking the cytogenetics place.

Oppenheimer’s Kevin DeGeeter suggests his positive outlook for the firm is partly dependent on Saphyr’s likely to impact other markets beyond cytogenetics for hematologic malignancies. Kinds in which the use of microarrays, FSH and karyotyping also “results in very long and high priced analytical choice trees.”

A latest examine posted in a peer-reviewed journal, provides credence to DeGeeter’s ambitions for Bionano.

“We watch publication this 7 days of a commentary in Genes as furnishing an crucial update on improvement of optical genome mapping (OGM) for one particular of the much larger new current market chances: prenatal cytogenetics,” the 5-star analyst mentioned. “Takeaways from paper include things like: 1) likely to replace microarrays, FSH and karyotyping in reflex location subsequent NIPT 2) four-day turnaround time for OGM and 3) potential for superior coverage of elaborate structural variants (SVs) which include Fragile X expansions.”

Non-invasive prenatal screening checks (NIPT) are set to turn out to be a prevalent put screening resource for pregnancies all in excess of the earth. Adhering to a good NIPT screen or for significant-chance pregnancies with an abnormal ultrasound, OGM could convey to the desk a high-throughput, in-depth and high-resolution observe up genome analysis.Saphyr’s ability to precisely detect aneuploidies, intercourse chromosome anomalies, microdeletion and microduplication syndromes and repeat growth and contraction issues were being highlighted by the study’s authors.

The addition of prenatal testing could also insert an extra earnings stream DeGeeter “conservatively estimates” this sector could include more than 500,000 cases, which equates to an more $250 million to Saphyr’s TAM (complete addressable current market).

Even with the stock gaining 155% on a calendar year-to-date basis, BNGO shares now sit 47% beneath the giddy heights notched in mid-February. DeGeeter excepts Bionano to claw again these gains Heading by the $15 selling price target, the shares will include 106% of muscle in excess of the up coming 12 months. (To enjoy DeGeeter’s track file, simply click here)

DeGeeter’s colleagues are reading from the same hymn sheet both of those other the latest opinions say Acquire, all coalescing to a Potent Buy consensus score. The regular selling price target now stands at $14.33, representing possible upside of 97%. (See BNGO stock examination on TipRanks)

To uncover good ideas for shares buying and selling at attractive valuations, pay a visit to TipRanks’ Finest Shares to Buy, a newly launched device that unites all of TipRanks’ equity insights.

Disclaimer: The viewpoints expressed in this article are only these of the highlighted analyst. The content is meant to be utilized for informational reasons only. It is really significant to do your very own evaluation just before building any expenditure.